Colgate-Palmolive (CL) beat expectations in FY2026 on revenue of $93.0B versus the $90.4B estimate (+18.1% YoY) and EPS of $1.59. Below is the full Colgate-Palmolive earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$93.0B (vs $90.4B est · +2.9% surprise · +18.1% YoY)
EPS
$1.59 (vs $1.52 est · +4.6% surprise · +9.5% YoY)
Share price
$82.49 (+2.0%)
Market cap
$800.0B
What you'll find
Next Colgate-Palmolive (CL) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Colgate-Palmolive reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Colgate-Palmolive (CL)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Colgate-Palmolive's next earnings date?
Colgate-Palmolive's (CL) next scheduled earnings date is Feb 4, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Colgate-Palmolive (CL) beat or miss earnings?
In FY2026, Colgate-Palmolive (CL) posted beat results — revenue of $93.0B versus the $90.4B estimate (+2.9% surprise) and EPS of $1.59 versus $1.52 expected (+4.6% surprise). Magnisto decodes every Colgate-Palmolive (CL) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Colgate-Palmolive (CL) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Colgate-Palmolive (CL), anchored to the current $82.49 share price, so you can weigh the bull, base and bear cases for Colgate-Palmolive side by side.
Is Colgate-Palmolive (CL) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Colgate-Palmolive fits your own thesis and risk profile. This is research, not investment advice.